For unresectable oligometastases or nonsurgical candidates, SBRT has a growing role with recent randomized phase II trial data indicating a doubling overall survival advantage for ablative SBRT in combination with systemic therapy versus systemic therapy alone. Proton radiation has also been prospectively demonstrated as an effective and safe choice for historically challenging scenarios, and in particular for larger tumors when normal liver sparing is otherwise difficult to achieve.